Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Completes Clinical Trial Enrollment for HPV Tests

NEW YORK (GenomeWeb News) - Third Wave Technologies said today that it has completed patient enrollment for a clinical trial involving its two human papillomavirus tests.
 
The company said it has enrolled 2,000 normal subjects and 1,400 women with atypical Pap test results. Next steps in the clinical trial include obtaining final colposcopy and biopsy data, validating and opening a database, and submitting pre-market approval applications to the US Food and Drug Administration.
 
The company said it expects to file for FDA approval for two HPV products in the first quarter of 2008. One is a test that will screen for 14 high-risk types of HPV and the other is a test for HPV types 16 and 18, the two most carcinogenic types of the virus.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.